Affiliation:
1. Department of Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1 Str., 02-097 Warsaw, Poland
2. Department of Psychiatry, Medical University of Warsaw, 00-665 Warsaw, Poland
3. Department of Medical Biology, Medical University of Bialystok, 15-222 Bialystok, Poland
Abstract
In recent months, there has been a new trend involving the consumption of Amanita muscaria. The aim of this article was to investigate the reasons for consumption, the form taken and the adverse symptoms that were indicated by those consuming Amanita muscaria. After analysing 5600 comments, 684 people were included in the study, who, in social media groups such as Facebook, stated the purpose of consuming the mushroom (n = 250), the form of mushroom they were taking (n = 198) or the adverse symptoms they experienced (n = 236). The gender of the subjects differentiated the parameters analysed. In the study group of women, the main purpose of consuming Amanita muscaria was to reduce pain, as well as to reduce skin problems, while in men it was mainly to relieve stress, reduce the severity of depressive symptoms and reduce insomnia (p < 0.001). With regard to the form of mushroom ingested, tincture was predominant in the women’s study group, while dried was predominant in the men (p < 0.001). In terms of side effects, women reported primarily headaches, while men reported nausea, vomiting, abdominal pain and drowsiness (p < 0.001). Advanced research on Amanita muscaria should be carried out to make the community aware of the toxicity of this fungus.
Subject
Chemical Health and Safety,Health, Toxicology and Mutagenesis,Toxicology
Reference32 articles.
1. New psychoactive substances: Challenges for drug surveillance, control, and public health responses;Peacock;Lancet,2019
2. The Council of the European Union (2023, April 09). Council Decision of 2 December 2010 on Submitting 4-Methylmethcathinone (Mephedrone) to Control Measures. Official Journal of the European Union. Available online: http://www.emcdda.europa.eu/attachements.cfm/att_134870_EN_Council_Decision_2010_759_EU_2_December_2010.pdf.
3. UK Parliament (2023, April 09). Psychoactive Substances Act 2016. Available online: http://services.parliament.uk/bills/2015-16/psychoactivesubstances.html.
4. The growing problem of mephedrone use in Warsaw, Poland, 2010–2018;Ordak;Lancet Psychiatry,2018
5. Manganese concentration in patients with encephalopathy following ephedrone use: A narrative review and analysis of case reports;Ordak;Clin. Toxicol.,2022
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献